ChemoCentryx, Inc.
TREATMENT OF C3 GLOMERULOPATHY USING A C5A INHIBITOR

Last updated:

Abstract:

Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.

Status:
Application
Type:

Utility

Filling date:

20 Dec 2021

Issue date:

18 Aug 2022